Clinical trials: Genital Neoplasms, Female
Head and Neck Cancer, Head and Neck Tumor
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at…
- Conditions
- Head and Neck Cancer, Head and Neck Tumor, Thoracic Tumor, Thoracic Cancer
- Trial name
- IMPROVE (NCT05053230)
- Testing
- IM@Home, Enhanced usual care
- Where
- 7 sites in United States
- Volunteers
- 324 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gynecologic Neoplasm, Brachytherapy
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
The goal of this open label, randomized, controlled clinical trial is to assess the benefits of providing Reiki therapy to subjects receiving their first brachytherapy treatment for gynecological malignancies.
- Conditions
- Gynecologic Neoplasm, Brachytherapy, Therapeutic Touch, Endometrial Cancer
- Trial name
- Reiki-Brachy (NCT05979610)
- Testing
- Reiki therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Utah
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs
Selumetinib and Olaparib in Solid Tumors
This study has 2 phases: Phase 1 (dose escalation) and Phase 2 (dose expansion). The goal of Phase 1 of this clinical research study is to find the highest tolerable dose combination of selumetinib and olaparib that can be given…
- Conditions
- Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs
- Trial name
- NCT03162627
- Testing
- Selumetinib, Olaparib
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells.
- Trial name
- NCT06952660
- Testing
- TIVDAK
- Where
- 132 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- Pfizer
Breast Neoplasm, Colorectal Neoplasm
Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer
This trial studies how well a decision aid website works in helping to make decisions about fertility in participants with cancer.
- Conditions
- Breast Neoplasm, Colorectal Neoplasm, Female Reproductive System Neoplasm, Health Care Provider
- Trial name
- NCT03141437
- Testing
- Best Practice, Educational Intervention, Internet-Based Intervention
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Corpus Uteri Cancer
INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations…
- Conditions
- Breast Cancer, Corpus Uteri Cancer, Ovary Cancer, Pancreas Cancer
- Trial name
- INSPIRE (NCT07671937)
- Testing
- INSPIRE (INtegrating Systematic PatIent-Reported Evaluations), Capture of patient-reported outcomes, Enhanced Clinician Awareness
- Where
- 3 sites in United States
- Volunteers
- 2,748 people
- Sponsor
- University of Alabama at Birmingham
Gynecologic Cancer, Gynecologic Neoplasm
Patient-Reported Outcomes Among Women Wtih Gynecological Cancer (The CONNECT Study)
Systematic nurse-led consultations based on electronic patient-reported outcomes (ePRO) will be tested among women with ovarian - and endometrial cancer receiving first-line chemotherapy.
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasm, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT04945187
- Testing
- Nurse-led consultations based on electronic patient-reported outcomes
- Where
- Denmark
- Volunteers
- 94 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Malignant Neoplasms of Female Genital Organs
Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers
The goal of this research study is to learn if a home-based physical activity program is feasible and can help endometrial cancer survivors lose weight.
- Trial name
- NCT02774759
- Testing
- Accelerometer, Questionnaires, Fitness Test
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Neoplasms of Female Genital Organs
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
The goal of this clinical research study is to learn if fulvestrant and abemaciclib can help to control low-grade serous ovarian cancer. The safety of this drug combination will also be studied. This is an investigational study.
- Trial name
- NCT03531645
- Testing
- Fulvestrant, Abemaciclib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product.
- Conditions
- Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT05617755
- Testing
- AB-1015
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Arsenal Biosciences, Inc.
Malignant Neoplasms of Female Genital Organs, Ovarian Cancer
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
The goal of this clinical research study is to learn if Avastin (bevacizumab) can help to control ovarian, fallopian, or primary peritoneal cancer that has been found during second-look surgery.
- Conditions
- Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02884648
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Advanced Solid Tumors, Breast Cancer
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/HER2- advanced and metastatic breast cancer, with…
- Conditions
- Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
- Trial name
- NCT07038369
- Testing
- ATV-1601, ATV-1601 + Fulvestrant
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 134 people
- Sponsor
- Atavistik Bio, Inc
Ovarian Cancer, Fallopian Tube Cancer
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
- Trial name
- NCT06906341
- Testing
- Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
- Where
- 49 sites in United States, Belgium and 6 more
- Volunteers
- 270 people
- Sponsor
- Corcept Therapeutics
Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by…
- Conditions
- Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx
- Trial name
- NCT03093909
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Breast Cancer
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
- Trial name
- NCT06533059
- Testing
- ALTA2618
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Alterome Therapeutics, Inc.
Gynecologic Cancer, Gynecologic Neoplasms
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Background: Tumors that have spread to the lining of the abdomen from other cancers, such as cancer of the appendix, colon, or ovary, are called peritoneal carcinomatosis. In most cases, outcomes are poor.
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms
- Trial name
- NCT05185947
- Testing
- Paclitaxel, Nilotinib, ECG
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
Some tumors are difficult to treat with chemotherapy or radiation. One of the reasons is that areas of the tumor do not have many blood vessels, which makes it difficult for drugs to reach those areas.
- Conditions
- Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System, Malignant Neoplasms of Female Genital Organs
- Trial name
- NCT03435952
- Testing
- Pembrolizumab, Clostridium Novyi-NT, Doxycycline
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Gynecologic Cancer, Gynecologic Neoplasm
The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study
This study compares traditional follow-up of gynaecological cancer patients to an alternative follow-up model. In the alternative follow-up model the patients will meet a nurse at every second consultation.
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasm, Ovarian Cancer, Endometrial Cancer
- Trial name
- LETSGO (NCT04122235)
- Testing
- LETSGO follow-up
- Where
- 12 sites in Norway
- Volunteers
- 755 people
- Sponsor
- Sorlandet Hospital HF
Oncology, Breast Cancer
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further…
- Conditions
- Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer
- Trial name
- MOMENTUM (NCT04075305)
- Testing
- Radiation therapy
- Where
- 18 sites in United States, Australia and 7 more
- Volunteers
- 8,000 people
- Sponsor
- UMC Utrecht